We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Expert Opinion / Cases · December 07, 2020

Metastatic Breast Cancer Treatment?

Written by
Ana C. Sandoval Leon MD


Discuss This item Follow

No comments yet, be the first to start the discussion!

  • luis betancourt


  • Volker Gressler

    Trastuzuamb +Pertuzumab +Fulvestrant

  • Silvana Costa

    Trastuzuamb + Pertuzumab + Fulvestrant

  • Oscar Rivero

    Trastuzumab + pertuzumab + fulvestrant

  • Kimberly Langdon

    Trastuzumab +pertuzumab + fulvestrant

  • souhila medrar

    trastuzumab +pertuzumab+ fulvestrant

  • Bogdan Cristian Dinu

    5 variant


    According to the HER2CLIMB trial, Tucatinib,Capecitabine,Trastuzumab. as there was a statistically significant improvement in both progression-free and overall survival in the tucatinib arm.

  • nadim nagi

    Tucatinib,Capcitabine,Trastuzumab as HER2CLIMB trial

  • Swapan Kumar   Nath

    Trastuzumab, Pertuzumab with fulvastrant is my choice

  • Jan 24, 2021

    Pending Moderator approval.

Further Reading